Literature DB >> 3245235

Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients.

P H Degen1, W Dieterle, W Schneider, W Theobald, U Sinterhauf.   

Abstract

1. The kinetics of diclofenac (I) and five of its metabolites (II-VI) were investigated in three healthy volunteers and in six patients. Compounds I-VI were measured by capillary column gas chromatography in plasma and urine. 2. After a single 100 mg dose of diclofenac sodium to volunteers, the drug was absorbed rapidly and showed peak plasma levels of 10-12 nmol/g. The maximum concentrations of five metabolites were comparatively low (0.36-2.94 nmol/g). The mono- and dihydroxy metabolites (II-V) had apparent terminal half-lives similar to that of I (1-3 h), but the hydroxymethoxy metabolite (VI) had a half-life of about 80 h. Renal elimination of VI within 96 h was about 1% of dose and that of I-VI was 36% (free plus conjugated). 3. Following daily treatment with 2 x 75 mg of an experimental sustained release formulation to patients for 6-10 months, steady-state trough concentrations of I-V in plasma were low (average values: 0.23-0.57 nmol/g). The mean trough concentration of VI was comparatively higher at 3.69 +/- 0.91 nmol/g presumably reflecting its accumulation. Despite this it is unlikely to contribute to the drug's therapeutic activity, since it has been shown in laboratory tests to be devoid of anti-inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3245235     DOI: 10.3109/00498258809042267

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Authors:  Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs.

Authors:  R L Oberle; H Das; S L Wong; K K Chan; R J Sawchuk
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

4.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

5.  Analysis of diclofenac and four of its metabolites in human urine by HPLC.

Authors:  R J Sawchuk; J A Maloney; L L Cartier; R J Rackley; K K Chan; H S Lau
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

6.  Pharmacological properties of five diclofenac metabolites identified in human plasma.

Authors:  I Wiesenberg-Boettcher; J Pfeilschifter; A Schweizer; A Sallmann; P Wenk
Journal:  Agents Actions       Date:  1991-09

7.  Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations.

Authors:  Christoph Thiel; Ines Smit; Vanessa Baier; Henrik Cordes; Brigida Fabry; Lars Mathias Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.